147 related articles for article (PubMed ID: 23133805)
1. Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist.
Buckle T; van Berg NS; Kuil J; Bunschoten A; Oldenburg J; Borowsky AD; Wesseling J; Masada R; Oishi S; Fujii N; van Leeuwen FW
Am J Nucl Med Mol Imaging; 2012; 2(1):99-109. PubMed ID: 23133805
[TBL] [Abstract][Full Text] [Related]
2. Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS.
Buckle T; Kuil J; van den Berg NS; Bunschoten A; Lamb HJ; Yuan H; Josephson L; Jonkers J; Borowsky AD; van Leeuwen FW
PLoS One; 2013; 8(1):e48324. PubMed ID: 23326303
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC.
van den Berg NS; Buckle T; Kuil J; Wesseling J; van Leeuwen FW
Transl Oncol; 2011 Aug; 4(4):234-40. PubMed ID: 21804919
[TBL] [Abstract][Full Text] [Related]
4. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors.
Hanaoka H; Mukai T; Tamamura H; Mori T; Ishino S; Ogawa K; Iida Y; Doi R; Fujii N; Saji H
Nucl Med Biol; 2006 May; 33(4):489-94. PubMed ID: 16720240
[TBL] [Abstract][Full Text] [Related]
5. Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.
Sand LGL; Buckle T; van Leeuwen FWB; Corver WE; Kruisselbrink AB; Jochemsen AG; Hogendoorn PCW; Szuhai K
BMC Cancer; 2017 May; 17(1):383. PubMed ID: 28549419
[TBL] [Abstract][Full Text] [Related]
6. [⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imaging.
Hartimath SV; Domanska UM; Walenkamp AM; Rudi A J O D; de Vries EF
Nucl Med Biol; 2013 May; 40(4):507-17. PubMed ID: 23522974
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression.
Kuil J; Buckle T; Oldenburg J; Yuan H; Borowsky AD; Josephson L; van Leeuwen FW
Mol Pharm; 2011 Dec; 8(6):2444-53. PubMed ID: 22085282
[TBL] [Abstract][Full Text] [Related]
10. Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.
Linde P; Baues C; Wegen S; Trommer M; Quaas A; Rosenbrock J; Celik E; Marnitz S; Bruns CJ; Fischer T; Schomaecker K; Wester HJ; Drzezga A; van Heek L; Kobe C
Cancer Imaging; 2021 Feb; 21(1):22. PubMed ID: 33579381
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia.
Schmid BC; Rudas M; Rezniczek GA; Leodolter S; Zeillinger R
Breast Cancer Res Treat; 2004 Apr; 84(3):247-50. PubMed ID: 15026622
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma.
Vag T; Steiger K; Rossmann A; Keller U; Noske A; Herhaus P; Ettl J; Niemeyer M; Wester HJ; Schwaiger M
EJNMMI Res; 2018 Sep; 8(1):90. PubMed ID: 30191351
[TBL] [Abstract][Full Text] [Related]
13. [
Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model.
Hartimath SV; van Waarde A; Dierckx RA; de Vries EF
Mol Pharm; 2014 Nov; 11(11):3810-7. PubMed ID: 25094028
[TBL] [Abstract][Full Text] [Related]
16. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel
Zhang X; You L; Chen S; Gao M; Guo Z; Du J; Lu J; Zhang X
J Labelled Comp Radiopharm; 2018 May; 61(5):438-446. PubMed ID: 29370457
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
